Who is sponsoring NCT01458639?

NCT01458639 is sponsored by Cyclomedica Australia PTY Limited.

What condition does NCT01458639 study?

NCT01458639 studies Pulmonary Embolism.

What drugs are being tested in NCT01458639?

Interventions: Technegas V SPECT imaging, Xenon-133 Ventilation Planar imaging.

What is the status of NCT01458639?

NCT01458639 is currently TERMINATED.

Last reviewed 2015-10-13 · How we verify

A Comparison of Technegas® Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging in Subjects Being Evaluated for Pulmonary Embolism

NCT01458639 Phase 3 TERMINATED Results posted

Phase 3 within-subject trial of Technegas V/Q SPECT and Tc-99m macro-aggregated albumin (MAA) imaging compared to Xenon-133 V/Q planar and Tc-99m macroaggregate of albumin (MAA) imaging for the diagnosis of Pulmonary Embolism (PE).

Details

Lead sponsor	Cyclomedica Australia PTY Limited
Phase	Phase 3
Status	TERMINATED
Enrolment	18
Start date	2012-08
Completion	2015-06

Conditions

Pulmonary Embolism

Interventions

Technegas V SPECT imaging
Xenon-133 Ventilation Planar imaging

Primary outcomes

Sensitivity of Technegas V/Q SPECT for the Diagnosis of PE — Prospective, 30 days follow-up
Compared to the sensitivity of Xenon V/Q Planar imaging. "Truth" based on blinded reader's assessments of V/Q SPECT images compared with subject's final diagnosis resulting from clinical information at 30 days follow-up.
Specificity of Technegas V/Q SPECT for the Diagnosis of PE. — Prospective, 30 days follow-up
Compared to the specificity of Xenon V/Q Planar imaging. "Truth" based on blinded reader's assessments of V/Q SPECT images compared with subject's final diagnosis resulting from clinical information at 30 days follow-up.

Countries

United States